Absci Corp rises after Needham initiates coverage with 'buy' rating

** Shares of AI biologics firm Absci Corp  ABSI.O  rise 3.7%
to $3.34 premarket 
    ** Brokerage Needham initiates coverage with a "buy" rating,
sets price target of $9 
    ** Brokerage says Absci stands out from the pack due to its
practical approach to drug development
     ** Says unlike many of its peers, Absci generates
proprietary, well-annotated, wet-lab data at scale, adds, "It is
our view that the real currency for companies focused on drug
development in the AI age is the quality of the data used" 
    ** Says co has potential best-in-class assets in high-value
therapeutic spaces such as inflammatory bowel disease
    ** 8 of 8 brokerages rate the stock "buy" or higher; their
median PT is $9
    ** ABSI had fallen 37.6% in 2024 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))

Recent news on AbSci

See all news